Skip to main content
Premium Trial:

Request an Annual Quote

Accelr8 Reports Preliminary FY2010 Revenues of $2.2M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Accelr8 Technology today reported preliminary revenues of $2.2 million for its fiscal year ended July 31, compared to revenues of $1.3 million for FY 2009.

The Denver-based firm also reported net income of $650,447 for the year, compared to a net loss of $714,197 for the previous year.

Accelr8 also noted that its total shareholders' equity was approximately $4.9 million. Last month, the firm had been notified by the NYSE Amex that it was still not in compliance with listing standards. In order to be listed, the exchange requires that a company have at least $4 million in stockholder equity if it has losses from continuing operations and net losses in three of the four most recent fiscal years.

In early Thursday trade, shares of Accelr8 were up 12 percent at $.90.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.